ArticleslgStudy

chemistry

Lubiprostone

Lubiprostone is a chemistry topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Lubiprostone rather than just read about it. In short: Lubiprostone, sold under the brand name Amitiza among others, is a medication used in the management of chronic idiopathic constipation, predominantly irritable bowel syndrome-associated constipation in women and opioid-induced constipation. The drug is owned by Mallinckrodt and is marketed by Takeda Pharmaceutical Company.

Lubiprostone — main illustration
Lubiprostone — illustration

Key takeaways

  • Lubiprostone belongs to chemistry; place it in that map before memorising details.
  • Learn the definition first, then one example that makes the definition concrete.
  • Connect Lubiprostone to a quantity you can measure, compute or draw — that is where exam questions come from.
  • Reproduce the core statement of Lubiprostone from memory before moving on to harder problems.

Reference excerpt

Lubiprostone, sold under the brand name Amitiza among others, is a medication used in the management of chronic idiopathic constipation, predominantly irritable bowel syndrome-associated constipation in women and opioid-induced constipation. The drug is owned by Mallinckrodt and is marketed by Takeda Pharmaceutical Company. The drug was developed by Sucampo Pharmaceuticals and approved by the Food and Drug Administration (FDA) in 2006. It was recommended for use in the UK by the National Institute for Health and Care Excellence (NICE) in July 2014. Health Canada approved the drug in 2015. Lubiprostone received approval from the Food and Drug Administration in 2008, to treat irritable bowel syndrome with constipation (IBS-C), and in 2013, for the treatment of opioid-induced constipation in adults with chronic noncancer pain. It is available as a generic medication.

Medical uses Lubiprostone is a laxative used for the treatment of constipation, specifically:

Chronic idiopathic constipation (difficult or infrequent passage of stools that lasts for 3 months or longer and is not caused by diet, disease, or drugs). Constipation caused by certain opioid (narcotic) pain medications in people with chronic (ongoing), noncancer pain, or in patients with long-lasting pain caused by a previous cancer or its treatment who do not need weekly increases in opioid dosage. The effectiveness of lubiprostone has not been established in patients who are taking a diphenylheptane opioid (e.g., methadone). Irritable bowel syndrome with constipation (IBS-C; a condition that causes stomach pain or cramps, bloating, and infrequent or difficult passage of stools) in women who are at least 18 years of age. Lubiprostone has not been studied in children. There is current research under way to determine the safety and efficacy in postoperative bowel dysfunction. It comes in a liquid filled capsule and is available only with a doctor's prescription. If one misses a dose it should be taken as soon as possible unless it is almost time for the next dose, in which case it should be skipped and the user should return to their regular dosing schedule.

Adverse effects In clinical trials, the most common adverse event was nausea (31%). Other adverse events (≥5% of patients) included diarrhea (13%), headache (13%), abdominal distension (5%), abdominal pain (5%), flatulence (6%), sinusitis (5%), vomiting (5%), and fecal incontinence (1%). The FDA lists the following: For subjects with chronic idiopathic constipation taking Amitiza:

Nausea ~ 29% (4% were severe, and 9% of patients discontinued treatment due to nausea. The rate of nausea was lower among male (8%) and elderly (19%) patients. No patients in the clinical studies were hospitalized due to nausea.) Diarrhea: ~12% (2% were severe, and 2% of patients discontinued treatment due to diarrhea) Several less common adverse reactions (<1%). For opioid-induced constipation:

Nausea: ~ 11%; 1% severe nausea and 2% discontinued treatment due to nausea. Diarrhea: ~ 8%; 2% severe diarrhea and 1% of patients discontinued treatment due to diarrhea. Less common adverse reactions (<1%): fecal incontinence, blood potassium decreased. For subjects with irritable bowel syndrome with constipation:

Nausea: ~ 8%; 1% severe nausea and 1% discontinued treatment due to nausea. Diarrhea: ~ 7%; <1% of patients had severe diarrhea and <1% of patients discontinued treatment due to diarrhea. Less common adverse reactions: <1% A 2018 pooled analysis from three phase III, randomized, double-blind, placebo-controlled studies on usage for Opioid-Induced Constipation, found that the numbers of patients reporting adverse effects were similar in both the lubiprostone and placebo treatment groups for all opioid classes (P ≥ 0.125); however, gastrointestinal adverse effects were reported more frequently by those receiving lubiprostone than 2 of the 3 opioid groups. The most commonly reported TEAEs in the lubiprostone treatment groups were nausea (13.4%–18.1%), diarrhea (1.2%–13.9%), and abdominal pain (4.7%–5.6%). In the population overall, the greatest likelihood of experiencing the first episode of any of these three TEAEs was greatest in the first week of treatment and decreased thereafter. According to Medscape, the most common (>10%) were: Nausea, Diarrhea (7-12%), Headache (2-11%). Less common side effects (1-10%) included: Abdominal pain (4-8%), Abdominal distension (3-6%), Flatulence (4-6%), Vomiting (3%), Loose stools (3%), Edema (1-3%), Abdominal discomfort (1-3%), Dizziness (3%), Chest discomfort/pain (2%), Dyspnea (2%), Dyspepsia (2%), Fatigue (2%), Dry mouth (1%).

Contraindications Known or suspected mechanical GI obstruction. Known hypersensitivity to lubiprostone or any ingredient in the formulation. The effects on pregnancy have not been studied in humans, but testing in guinea pigs resulted in fetal loss. Lubiprostone is contraindicated in people exhibiting chronic diarrhea, bowel obstruction, or diarrhea-predominant irritable bowel syndrome.

Mechanism of action Lubiprostone is a bicyclic fatty acid derived from prostaglandin E1 that acts by specifically activating ClC-2 chloride channels on the apical aspect of gastrointestinal epithelial cells, producing a chloride-rich fluid secretion. These secretions soften the stool, increase intestinal transit and decrease gastric emptying, and promote spontaneous bowel movements.

Pharmacokinetics Unlike many laxative products, lubiprostone does not show signs of drug tolerance, chemical dependency, or altered serum electrolyte concentration. Minimal distribution of the drug occurs beyond the immediate gastrointestinal tissues. Lubiprostone is rapidly metabolized by reduction/oxidation, mediated by carbonyl reductase. There is no metabolic involvement of the hepatic cytochrome P450 system. The measurable metabolite, M3, exists in very low levels in plasma and makes up less than 10% of the total administered dose. Data indicate that metabolism occurs locally in the stomach and jejunum.

Society and culture

Economics The cost to the NHS was £29.68 per 24 mcg 28-cap pack as of April 2017.

Brand names Lubiprostone is available in the United States, Japan, Switzerland, India, Bangladesh, the United Kingdom, and Canada. In Bangladesh and India, lubiprostone is sold under the brand name Lubigut by Ziska Pharmaceuticals, Lubilax by Beacon Pharmaceuticals, and under the brand name Lubowel by Sun Pharmaceutical.

References

Illustrations

Lubiprostone illustration

Worked examples

Example 1 — a first encounter with Lubiprostone

Start with the simplest possible case. Write down what Lubiprostone claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In chemistry, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Lubiprostone before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Lubiprostone ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Lubiprostone

In research
Lubiprostone appears in chemistry research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry
Engineering practice reuses Lubiprostone in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom
Lubiprostone is common in secondary-school and first-year university syllabi. It links to neighbouring topics Drugs acting on the gastrointestinal system and metabolism, Drugs developed by Takeda Pharmaceutical Company, Fatty acids, so understanding it makes those chapters shorter.
In everyday life
Look for Lubiprostone outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.
Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Lubiprostone” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Lubiprostone in 20 minutes

  1. Read the reference excerpt below once, without taking notes.
  2. Close the page and write down what Lubiprostone means in your own words.
  3. Compare your version with the excerpt and mark what you missed.
  4. Work through the three examples above with pen and paper.
  5. Explain Lubiprostone out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Lubiprostone in simple terms?

Lubiprostone, sold under the brand name Amitiza among others, is a medication used in the management of chronic idiopathic constipation, predominantly irritable bowel syndrome-associated constipation in women and opioid-induced constipation. The drug is owned by Mallinckrodt and is marketed by Take…

Why does Lubiprostone matter?

Because it connects several chemistry ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Lubiprostone?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Lubiprostone.

Tags

  • Drugs acting on the gastrointestinal system and metabolism
  • Drugs developed by Takeda Pharmaceutical Company
  • Fatty acids
  • Heterocyclic compounds with 2 rings
  • Ketones
  • Lactols
  • Laxatives
  • Organofluorides
  • Oxygen heterocycles

Keep exploring